Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 10, 2010 - Issue 3
Submit an article Journal homepage
363
Views
55
CrossRef citations to date
0
Altmetric
Drug Evaluations

Farletuzumab in epithelial ovarian carcinoma

Whitney A Spannuth University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology, 1155 Herman Pressler Drive, CPB6.3244, Houston, TX 77030-3271, USA +1 713 745 3357; +1 713 792 7586; [email protected]
,
Anil K Sood University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology, 1155 Herman Pressler Drive, CPB6.3244, Houston, TX 77030-3271, USA +1 713 745 3357; +1 713 792 7586; [email protected]; University of Texas MD Anderson Cancer Center, Department of Cancer Biology, 1155 Herman Pressler Drive, Houston, TX 77030-3271, USA; University of Texas MD Anderson Cancer Center, Center for RNA Interference and Non-Coding RNA, 1155 Herman Pressler Drive, Houston, TX 77030-3271, USA
&
Robert L Coleman University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology, 1155 Herman Pressler Drive, CPB6.3244, Houston, TX 77030-3271, USA +1 713 745 3357; +1 713 792 7586; [email protected]; University of Texas MD Anderson Cancer Center, Center for RNA Interference and Non-Coding RNA, 1155 Herman Pressler Drive, Houston, TX 77030-3271, USA
Pages 431-437 | Published online: 22 Jan 2010

Citations (55)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (12)

Rebecca L. Porter & Ursula A. Matulonis. (2023) Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer. Expert Review of Anticancer Therapy 23:8, pages 783-796.
Read now
Seiya Sato & Hiroaki Itamochi. (2016) Profile of farletuzumab and its potential in the treatment of solid tumors. OncoTargets and Therapy 9, pages 1181-1188.
Read now
Gulden Menderes, Carlton L. Schwab, Jonathan Black & Alessandro D. Santin. (2016) The Role of the Immune System in Ovarian Cancer and Implications on Therapy. Expert Review of Clinical Immunology 12:6, pages 681-695.
Read now
Srinivas Ganta, Amit Singh, Yashesh Rawal, Joseph Cacaccio, Niravkumar R. Patel, Praveen Kulkarni, Craig F. Ferris, Mansoor M. Amiji & Timothy P. Coleman. (2016) Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer. Drug Delivery 23:3, pages 958-970.
Read now
Christian Ndong, Seiko Toraya-Brown, Katsiaryna Kekalo, Ian Baker, Tillman U Gerngross, Steven N Fiering & Karl E Griswold. (2015) Antibody-mediated targeting of iron oxide nanoparticles to the folate receptor alpha increases tumor cell association in vitro and in vivo. International Journal of Nanomedicine 10, pages 2595-2617.
Read now
Giuseppe Bronte, Francesca Lo Vullo, Gianfranco Pernice, Antonio Galvano, Eugenio Fiorentino, Giuseppe Cicero, Viviana Bazan, Christian Rolfo & Antonio Russo. (2015) Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy. Expert Opinion on Investigational Drugs 24:1, pages 125-132.
Read now
Allison J Ambrosio, Daphne Suzin, Edwin L Palmer & Richard T Penson. (2014) Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer. Expert Review of Clinical Pharmacology 7:4, pages 443-450.
Read now
Umberto Leone Roberti Maggiore, Filippo Bellati, Ilary Ruscito, Maria Luisa Gasparri, Franco Alessandri, Pier Luigi Venturini & Simone Ferrero. (2013) Monoclonal antibodies therapies for ovarian cancer. Expert Opinion on Biological Therapy 13:5, pages 739-764.
Read now
Anumita Chaudhury, Surajit Das, Ralph M Bunte & Gigi NC Chiu. (2012) Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft. International Journal of Nanomedicine 7, pages 739-751.
Read now
Lesheng Teng, Jing Xie, Lirong Teng & Robert J Lee. (2012) Clinical translation of folate receptor-targeted therapeutics. Expert Opinion on Drug Delivery 9:8, pages 901-908.
Read now
Brian M Slomovitz, Michael J Worley, Maurie Markman & Robert L Coleman. (2011) Emerging therapeutics for primary peritoneal cancer. Expert Opinion on Emerging Drugs 16:1, pages 71-84.
Read now
Daniel R. Getts, Meghann T. Getts, Derrick P. McCarthy, Emily ML Chastain & Stephen D. Miller. (2010) Have we overestimated the benefit of human(ized) antibodies?. mAbs 2:6, pages 682-694.
Read now

Articles from other publishers (43)

Eduardo Gonzalez-Ochoa, Ana C Veneziani & Amit M Oza. (2023) Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer. Clinical Medicine Insights: Oncology 17.
Crossref
Shannon N. Westin, Anil K. Sood & Robert L. Coleman. 2023. DiSaia and Creasman Clinical Gynecologic Oncology. DiSaia and Creasman Clinical Gynecologic Oncology 464 488.e11 .
Yosuke Matsuura, Junji Ichinose, Masayuki Nakao, Sakae Okumura & Mingyon Mun. (2019) Recent fluorescence imaging technology applications of indocyanine green in general thoracic surgery. Surgery Today 50:11, pages 1332-1342.
Crossref
Sugapriya Dhanasekaran. (2019) Augmented cytotoxic effects of paclitaxel by curcumin induced overexpression of folate receptor-α for enhanced targeted drug delivery in HeLa cells. Phytomedicine 56, pages 279-285.
Crossref
Vahideh Tarhriz, Mojgan Bandehpour, Siavoush Dastmalchi, Elaheh Ouladsahebmadarek, Habib Zarredar & Shirin Eyvazi. (2018) Overview of CD24 as a new molecular marker in ovarian cancer. Journal of Cellular Physiology 234:3, pages 2134-2142.
Crossref
Andrew D. Newton, Jarrod D. Predina, Shuming Nie, Philip S. Low & Sunil Singhal. (2018) Intraoperative fluorescence imaging in thoracic surgery. Journal of Surgical Oncology 118:2, pages 344-355.
Crossref
Kathleen N Moore, Lainie P Martin, David M O'Malley, Ursula A Matulonis, Jason A Konner, Ignace Vergote, Jose F Ponte & Michael J Birrer. (2018) A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncology 14:2, pages 123-136.
Crossref
Shannon N. Westin, Anil K. Sood & Robert L. Coleman. 2018. Clinical Gynecologic Oncology. Clinical Gynecologic Oncology 470 492.e10 .
Kathleen N. Moore, Hossein Borghaei, David M. O'Malley, Woondong Jeong, Shelly M. Seward, Todd M. Bauer, Raymond P. Perez, Ursula A. Matulonis, Kelli L. Running, Xiaoyan Zhang, Jose F. Ponte, Rodrigo Ruiz-Soto & Michael J. Birrer. (2017) Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. Cancer 123:16, pages 3080-3087.
Crossref
Jose F. Ponte, Olga Ab, Leanne Lanieri, Jenny Lee, Jennifer Coccia, Laura M. Bartle, Marian Themeles, Yinghui Zhou, Jan Pinkas & Rodrigo Ruiz-Soto. (2016) Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia 18:12, pages 775-784.
Crossref
Even Walseng, Christopher G. Nelson, Junpeng Qi, Alex R. Nanna, William R. Roush, Rajib K. Goswami, Subhash.C. Sinha, Terrence R. BurkeJr.Jr. & Christoph Rader. (2016) Chemically Programmed Bispecific Antibodies in Diabody Format. Journal of Biological Chemistry 291:37, pages 19661-19673.
Crossref
Priyanka Bhatt, Imran Vhora, Sushilkumar Patil, Jitendra Amrutiya, Chandrali Bhattacharya, Ambikanandan Misra & Rajashree Mashru. (2016) Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. Journal of Controlled Release 226, pages 148-167.
Crossref
Daniel J O’Shannessy, Elizabeth B Somers, Li-chong Wang, Hongwei Wang & Ruby Hsu. (2015) Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers. Journal of Ovarian Research 8:1.
Crossref
Keith L. Knutson, Lavakumar Karyampudi, Purushottam Lamichhane & Claudia Preston. (2014) RETRACTED ARTICLE: Targeted immune therapy of ovarian cancer. Cancer and Metastasis Reviews 34:1, pages 53-74.
Crossref
Álvaro Henrique Ingles Garces, Mariane Sousa Fontes Dias, Eduardo Paulino, Carlos Gil Moreira Ferreira & Andréia Cristina de Melo. (2014) Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target?. Cancer Chemotherapy and Pharmacology 75:2, pages 221-234.
Crossref
Marie Bartouskova, Bohuslav Melichar & Beatrice Mohelnikova-Duchonova. (2015) Folate receptor: a potential target in ovarian cancer. Pteridines 26:1, pages 1-12.
Crossref
M Köbel, J Madore, S J Ramus, B A Clarke, P D P Pharoah, S Deen, D D Bowtell, K Odunsi, U Menon, C Morrison, S Lele, W Bshara, L Sucheston, M W Beckmann, A Hein, F C Thiel, A Hartmann, D L Wachter, M S Anglesio, E Høgdall, A Jensen, C Høgdall, K R Kalli, B L Fridley, G L Keeney, Z C Fogarty, R A Vierkant, S Liu, S Cho, G Nelson, P Ghatage, A Gentry-Maharaj, S A Gayther, E Benjamin, M Widschwendter, M P Intermaggio, B Rosen, M Q Bernardini, H Mackay, A Oza, P Shaw, M Jimenez-Linan, K E Driver, J Alsop, M Mack, J M Koziak, H Steed, C Ewanowich, A DeFazio, G Chenevix-Trench, S Fereday, B Gao, S E Johnatty, J George, L Galletta, E L Goode, S K Kjær, D G Huntsman, P A Fasching, K B Moysich, J D Brenton & L E Kelemen. (2014) Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. British Journal of Cancer 111:12, pages 2297-2307.
Crossref
Katarzyna Terlikowska, Anna Witkowska, Malgorzata Zujko, Bozena Dobrzycka & Slawomir Terlikowski. (2014) Potential Application of Curcumin and Its Analogues in the Treatment Strategy of Patients with Primary Epithelial Ovarian Cancer. International Journal of Molecular Sciences 15:12, pages 21703-21722.
Crossref
Whitney S Graybill & Robert L Coleman. (2014) Vintafolide: a novel targeted agent for epithelial ovarian cancer. Future Oncology 10:4, pages 541-548.
Crossref
V. Lavoué, F. Foucher, S. Henno, E. Bauville, V. Catros, F. Cabillic & J. Levêque. (2014) L’immunothérapie dans le cancer épithélial de l’ovaire : entre espoir et réalité. Journal de Gynécologie Obstétrique et Biologie de la Reproduction 43:3, pages 198-210.
Crossref
Daniel O'Shannessy, Stephen Jackson, Natalie Twine, Bryan Hoffman, Zoltan Dezso, Sergei Agoulnik & Elizabeth Somers. (2013) Gene Expression Analyses Support Fallopian Tube Epithelium as the Cell of Origin of Epithelial Ovarian Cancer. International Journal of Molecular Sciences 14:7, pages 13687-13703.
Crossref
Deborah K. Armstrong, Allen J. White, Susan C. Weil, Martin Phillips & Robert L. Coleman. (2013) Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecologic Oncology 129:3, pages 452-458.
Crossref
Elisabeth Smolle, Valentin Taucher, Martin Pichler, Edgar Petru, Sigurd Lax & Johannes Haybaeck. (2013) Targeting Signaling Pathways in Epithelial Ovarian Cancer. International Journal of Molecular Sciences 14:5, pages 9536-9555.
Crossref
Daniel J. O?Shannessy, Elizabeth B. Somers, Robert Smale & Yao-Shi Fu. (2013) Expression of Folate Receptor-? (FRA) in Gynecologic Malignancies and its Relationship to the Tumor Type. International Journal of Gynecological Pathology 32:3, pages 258-268.
Crossref
Daniel J O’Shannessy, Elizabeth B Somers, Julia Maltzman, Robert Smale & Yao-Shi Fu. (2012) Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. SpringerPlus 1:1.
Crossref
Sophia N. Karagiannis, Debra H. Josephs, Panagiotis Karagiannis, Amy E. Gilbert, Louise Saul, Sarah M. Rudman, Tihomir Dodev, Alexander Koers, Philip J. Blower, Christopher Corrigan, Andrew J. Beavil, James F. Spicer, Frank O. Nestle & Hannah J. Gould. (2011) Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunology, Immunotherapy 61:9, pages 1547-1564.
Crossref
Imran Rizvi, Tri A. Dinh, Weiping Yu, Yuchiao Chang, Margaret E. Sherwood & Tayyaba Hasan. (2012) Photoimmunotherapy and Irradiance Modulation Reduce Chemotherapy Cycles and Toxicity in a Murine Model for Ovarian Carcinomatosis: Perspective and Results. Israel Journal of Chemistry 52:8-9, pages 776-787.
Crossref
Huiting Cui, Joshua D. Thomas, Terrence R. BurkeJr.Jr. & Christoph Rader. (2012) Chemically Programmed Bispecific Antibodies That Recruit and Activate T Cells. Journal of Biological Chemistry 287:34, pages 28206-28214.
Crossref
B. A. Kamen & A. K. Smith. (2012) Farletuzumab, an anti-folate receptor ? antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro. Cancer Chemotherapy and Pharmacology 70:1, pages 113-120.
Crossref
Maria Ines Nunez, Carmen Behrens, Denise M. Woods, Heather Lin, Milind Suraokar, Humam Kadara, Wayne Hofstetter, Neda Kalhor, J. Jack Lee, Wilbur Franklin, David J. Stewart & Ignacio I. Wistuba, MD. (2012) High Expression of Folate Receptor Alpha in Lung Cancer Correlates with Adenocarcinoma Histology and Mutation. Journal of Thoracic Oncology 7:5, pages 833-840.
Crossref
Daniel J. O'Shannessy, Gordon Yu, Robert Smale, Yao-Shi Fu, Sunil Singhal, Robert P. Thiel, Elizabeth B. Somers & Anil Vachani. (2012) Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance. Oncotarget 3:4, pages 414-425.
Crossref
Lucia M. A. Crane, Henriette J. G. Arts, Marleen van Oosten, Philip S. Low, Ate G. J. van der Zee, Gooitzen M. van Dam & Joost Bart. (2011) The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cellular Oncology 35:1, pages 9-18.
Crossref
René H.M. Verheijen, David Cibula, Paolo Zola & Nicolas Reed. (2012) Cancer Antigen 125. International Journal of Gynecological Cancer 22:1, pages 170-174.
Crossref
Shannon N. Westin, Anil K. Sood & Robert L. Coleman. 2012. Clinical Gynecologic Oncology. Clinical Gynecologic Oncology 539 560.e6 .
Ben Davidson. 2012. Serous Effusions. Serous Effusions 167 203 .
Alberto Zacchetti, Franck Martin, Elena Luison, Angela Coliva, Emilio Bombardieri, Marcello Allegretti, Mariangela Figini & Silvana Canevari. (2011) Antitumor Effects of a Human Dimeric Antibody Fragment 131 I-AFRA-DFM5.3 in a Mouse Model for Ovarian Cancer . Journal of Nuclear Medicine 52:12, pages 1938-1946.
Crossref
Sanjib Bhattacharyya, Jameel Ahmad Khan, Geoffry L. Curran, J. David Robertson, Resham Bhattacharya & Priyabrata Mukherjee. (2011) Efficient Delivery of Gold Nanoparticles by Dual Receptor Targeting. Advanced Materials 23:43, pages 5034-5038.
Crossref
Vinochani Pillay, Hui K. Gan & Andrew M. Scott. (2011) Antibodies in oncology. New Biotechnology 28:5, pages 518-529.
Crossref
Lucia M.A. CraneMarleen van OostenRick G. PleijhuisArash MotekallemiSean C. DowdyWilliam A. ClibyAte G.J. van der ZeeGooitzen M. van Dam. (2011) Intraoperative Imaging in Ovarian Cancer: Fact or Fiction?. Molecular Imaging 10:4, pages 7290.2011.00004.
Crossref
Claudia C Preston, Ellen L Goode, Lynn C Hartmann, Kimberly R Kalli & Keith L Knutson. (2011) Immunity and immune suppression in human ovarian cancer. Immunotherapy 3:4, pages 539-556.
Crossref
Filippo Bellati, Chiara Napoletano, Maria Luisa Gasparri, Valeria Visconti, Ilaria Grazia Zizzari, Ilary Ruscito, Jlenia Caccetta, Aurelia Rughetti, Pierluigi Benedetti-Panici & Marianna Nuti. (2011) Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View. Clinical and Developmental Immunology 2011, pages 1-16.
Crossref
Wei Xia & Philip S. Low. (2010) Folate-Targeted Therapies for Cancer. Journal of Medicinal Chemistry 53:19, pages 6811-6824.
Crossref
J.A. Ledermann & R.S. Kristeleit. (2010) Optimal treatment for relapsing ovarian cancer. Annals of Oncology 21, pages vii218-vii222.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.